Deep Breath Intelligence develops breath analysis technology that employs gas chromatography and mass spectrometry to identify biomarkers in exhaled breath. This technology enhances diagnostic accuracy for respiratory and metabolic conditions, providing valuable insights for medical research and clinical practice.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing and monitoring respiratory and metabolic conditions often rely on invasive procedures like blood sampling, or require specialized equipment and frequent visits to healthcare providers. These methods can be inconvenient, costly, and may not always provide a complete picture of a patient's condition in real-time.
Solution
Deep Breath Intelligence (DBI) offers non-invasive breath analysis solutions that utilize gas chromatography and mass spectrometry in conjunction with machine learning algorithms to identify biomarkers in exhaled breath. This technology enables real-time monitoring of drug concentrations, detection of metabolic changes, and early diagnosis of diseases. DBI's flagship product, DBI-EPIbreath®, is a CE-certified test for drug monitoring in epilepsy, estimating valproic acid concentrations and risks of side effects from a single exhaled breath. The company's technology aims to improve precision medicine by providing healthcare providers with comprehensive pharmacokinetic and pharmacodynamic insights, facilitating personalized treatment plans and better patient outcomes.
Target Audience
DBI's primary customers include healthcare providers (e.g., neurologists, pulmonologists, general practitioners), medical researchers, and individuals seeking personalized health management solutions.
Features
- Non-invasive breath analysis using gas chromatography and mass spectrometry (GC-MS)
- Machine learning algorithms for biomarker identification and data analysis
- Real-time monitoring of drug concentrations and metabolic changes
- DBI-EPIbreath®: CE-certified test for valproic acid monitoring in epilepsy
- Identification of metabolic pathways associated with drug side effects and treatment response
- Potential applications in respiratory diseases, Long Covid, lung cancer, and metabolic disorders
- Study services for research and validation of breath biomarkers